-
Rosiglitazone and the Next Frontier of Fat Browning
2026-08-25
Rosiglitazone is more than a classic PPARγ tool: it can serve as a pharmacological benchmark for separating adipogenesis, insulin sensitivity, and thermogenic remodeling. When paired with the SETD7–Adcy7–Sirt1–CREB1 framework, Brl-49653 helps translational researchers design sharper experiments around white adipose browning and metabolic resilience.
-
Multiple Myeloma Cell-Line Mutations and Drug Resistance
2026-08-25
Vikova and colleagues provide a large-scale exome-based map of mutations across human multiple myeloma cell lines, linking recurrent genomic alterations with cancer pathways and drug-response phenotypes. The study offers a practical framework for selecting genetically relevant models and interpreting resistance experiments in hematological malignancy research.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-08-24
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in experimental kidney injury models and tubular epithelial cells, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transdifferentiation, inflammatory signaling, and Smad3/STAT3 activation.
-
Adipose-Neural Signaling in Cardiac Arrhythmia
2026-08-24
Fan et al. developed a stem cell-based coculture model showing how epicardial adipose tissue can promote cardiac arrhythmia through a leptin–sympathetic neuron–NPY/Y1R pathway. The study links this signaling axis to NCX and CaMKII activity and provides a mechanistic framework for evaluating adipose-neural contributions to atrial fibrillation and related electrical disorders.
-
Rotigotine: Dopamine D2/D3 Agonist Workflows
2026-08-23
Rotigotine supports integrated Parkinson’s disease research, from receptor-proximal cell assays to motor, neuroprotective, and depression-model studies. This practical guide emphasizes dose selection, locomotor confound control, formulation, and workflow decisions that improve interpretability.
-
MLKL Polymerization, Lysosomes, and Necroptosis
2026-08-22
The reference study identifies lysosomal membrane permeabilization as a mechanistic link between MLKL polymerization and necroptotic plasma membrane rupture. Its imaging, perturbation, and cathepsin B experiments suggest that lysosomal damage and protease release are active execution steps rather than secondary consequences of cell death.
-
Engineering RNA to Probe Mitochondrial Proteostasis
2026-08-22
A mechanistic study of TCAIM-mediated OGDH degradation illustrates how selective mitochondrial proteostasis can reshape metabolism. This thought-leadership perspective connects that biology to disciplined in vitro RNA engineering, showing where the HyperScribe™ Poly (A) Tailing Kit can strengthen translational experiments while distinguishing established evidence from workflow hypotheses.
-
Shaped ABC Coil-Bottlebrush Terpolymer Self-Assembly
2026-08-21
This study examines how sequence and side-chain shape control the phase behavior of ABC coil–bottlebrush triblock terpolymers. SAXS revealed robust segregation but unexpected suppression of double-gyroid formation and unusually slow structural ordering, providing design constraints for large-period network materials.
-
Topotecan HCl: From DNA Lesions to Translation
2026-08-20
Topotecan HCl is more than a cytotoxic reagent: it is a controllable probe of replication-associated DNA damage, response kinetics, and treatment scheduling. This thought-leadership guide connects topoisomerase 1 biology with assay design, model selection, toxicity interpretation, and translational strategy.
-
CHIR-99021 Workflows for Stem Cell Differentiation
2026-08-20
CHIR-99021 (CT99021) gives researchers a controllable way to tune GSK-3 activity across pluripotency, neural crest, corneal endothelial, and cardiac differentiation workflows. This guide translates Wnt timing, reagent handling, assay checkpoints, and troubleshooting into practical experimental decisions.
-
Resazurin Sodium Salt: Mechanism and Assay Use
2026-08-19
Resazurin sodium salt is a fluorogenic oxidation-reduction indicator for metabolic cell proliferation and cytotoxicity measurements. Its reduction to fluorescent resorufin supports scalable viability workflows, but exposure time, concentration, solvent, and product accumulation can affect interpretation.
-
Abiraterone acetate in 3D Prostate Cancer Models
2026-08-19
Use Abiraterone acetate as a mechanistically focused CYP17 inhibitor in prostate cancer assays, then test whether androgen pathway suppression translates into changes in patient-derived 3D spheroids. This workflow pairs biochemical exposure control with orthogonal viability, PSA, AR, and tissue-marker readouts to distinguish pathway resistance from delivery or assay failure.
-
Hypoxia and Immunometabolism in the Tumor Microenvironment
2026-08-18
The 2025 Cancer Letters review integrates tumor hypoxia, nutrient competition, and immune-cell metabolic dysfunction into a unified model of immunosuppressive tumor-microenvironment formation. Its main practical contribution is a framework for connecting HIF signaling and glucose-centered metabolic adaptation with immune evasion, while identifying both opportunities and limitations for metabolism-based therapies.
-
Ridaforolimus Workflows for mTOR Cancer Research
2026-08-18
Build reproducible mTOR signaling, proliferation, apoptosis, and angiogenesis workflows with Ridaforolimus (Deforolimus, MK-8669). This guide connects dose-controlled cancer assays with machine-learning-informed senescence experiments while emphasizing controls, interpretation, and troubleshooting.
-
Gemcitabine: DNA Damage and Cancer Assays
2026-08-17
Gemcitabine is a fluorinated deoxycytidine analog and DNA synthesis inhibitor used in cancer research, apoptosis assays, and DNA damage response studies. Its product-reported checkpoint activity and preclinical anti-tumor effects complement evidence that metabolic intervention can improve gemcitabine and cisplatin responses in cholangiocarcinoma.